Literature DB >> 12605644

Erythropoietin as an angiogenic factor in gastric carcinoma.

D Ribatti1, A Marzullo, B Nico, E Crivellato, R Ria, A Vacca.   

Abstract

AIMS: Previous studies have shown that increased vascularity is associated with haematogenous metastasis and poor prognosis in gastric cancer. The role of erythropoietin (Epo) in angiogenesis has not been completely clarified, although its involvement has been reported. In this study we correlated microvascular density and Epo receptor (Epo-R) expression in endothelial and tumour cells with histopathological type in gastric cancer. METHODS AND
RESULTS: Specimens of primary gastric adenocarcinomas obtained from 40 patients who had undergone curative gastrectomy were investigated immunohistochemically by using anti-CD31 and anti-Epo-R antibodies. Stage IV gastric carcinoma had a higher degree of vascularization than other stages, and Epo-R expression in both endothelial and tumour cells increased in parallel with malignancy grade and was highly correlated with the extent of angiogenesis.
CONCLUSIONS: Epo-R level correlates with angiogenesis and progression of patients with gastric carcinoma and we suggest that Epo might have a trophic effect on the vasculature of the gastrointestinal tract. Understanding mechanisms of gastric cancer angiogenesis provides a basis for a rational approach to the development of an anti-angiogenic therapy in patients with gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605644     DOI: 10.1046/j.1365-2559.2003.01581.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  18 in total

1.  Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

Authors:  Ahmed Mohyeldin; Huasheng Lu; Clifton Dalgard; Stephen Y Lai; Noam Cohen; Geza Acs; Ajay Verma
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

2.  Expression profile as predictor of relapse after adjuvant treatment in gastric cancer.

Authors:  María Sereno; Javier De Castro; Paloma Cejas; Miguel Angel García-Cabezas; Cristóbal Belda; Enrique Casado; Jaime Feliu; César Gómez; Miriam López; Manuel González Barón
Journal:  J Gastrointest Cancer       Date:  2012-06

3.  Erythropoietin and erythropoietin receptor in hepatocellular carcinoma: correlation with vasculogenic mimicry and poor prognosis.

Authors:  Zhihong Yang; Baocun Sun; Xiulan Zhao; Bing Shao; Jindan An; Qiang Gu; Yong Wang; Xueyi Dong; Yanhui Zhang; Zhiqiang Qiu
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

4.  Prognostic significance of erythropoietin and erythropoietin receptor in gastric adenocarcinoma.

Authors:  Lin Wang; Hai-Gang Li; Zhong-Sheng Xia; Jian-Ming Wen; Jun Lv
Journal:  World J Gastroenterol       Date:  2011-09-14       Impact factor: 5.742

5.  Erythropoietin is involved in angiogenesis in human primary melanoma.

Authors:  Domenico Ribatti; Beatrice Nico; Maria Teresa Perra; Vito Longo; Cristina Maxia; Tiziana Annese; Franca Piras; Daniela Murtas; Paola Sirigu
Journal:  Int J Exp Pathol       Date:  2010-08-27       Impact factor: 1.925

6.  Expression and functional significance of the erythropoietin receptor in hepatocellular carcinoma.

Authors:  Milljae Shin; Doopyo Hong; Zhengyun Zhang; You Min Kim; Wookjong Lee; Jae-Won Joh; Sung-Joo Kim
Journal:  HPB (Oxford)       Date:  2013-03-15       Impact factor: 3.647

7.  Safety of intravitreally administered recombinant erythropoietin (an AOS thesis).

Authors:  James C Tsai
Journal:  Trans Am Ophthalmol Soc       Date:  2008

8.  Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma.

Authors:  Keiichi Ito; Hidehiko Yoshii; Takako Asano; Akio Horiguchi; Makoto Sumitomo; Masamichi Hayakawa; Tomohiko Asano
Journal:  Exp Ther Med       Date:  2012-03-13       Impact factor: 2.447

9.  Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care.

Authors:  Christina Lönnroth; Marie Svensson; Wenhua Wang; Ulla Körner; Peter Daneryd; Ola Nilsson; Kent Lundholm
Journal:  Med Oncol       Date:  2007-09-11       Impact factor: 3.064

Review 10.  Effects of recombinant erythropoietin on breast cancer-initiating cells.

Authors:  Tiffany M Phillips; Kwanghee Kim; Erina Vlashi; William H McBride; Frank Pajonk
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.